Genomic Health, Pfizer to Co-Develop Renal Cancer Dx Based on Oncotype DX Platform
January 09, 2008
Genomic Health, Pfizer to Co-Develop Renal Cancer Dx Based on Oncotype DX Platform
The alliance pairs Genomic Health’s tried-and-tested Oncotype DX diagnostic platform with Pfizer’s sway with payors, which could widen adoption of the technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- AB Sciex API 3200MD and 3200MD QTRAP Mass Specs Receive EU CE-IVDD Mark
May 24, 2013 / ProteoMonitor - Ridge Diagnostics Announces Launch of Proteomic Test for Major Depressive Disorder
May 24, 2013 / ProteoMonitor - European Clinical Geneticists Wary of DTC Testing
May 24, 2013 / GenomeWeb Daily News - Qiagen, BioBay Open Translational Medicine Center in China
May 24, 2013 / GenomeWeb Daily News - Study Suggests Genetic Susceptibility to T2D May Have Shifted with Human Migration
May 24, 2013 / GenomeWeb Daily News